Abstract Details

Title Mid and Long-term Neurological and Neuropsychiatric Manifestations of Post-COVID-19 Syndrome: A Meta-analysis

Topic Infectious Disease

Presentation(s) N6 - Neuroscience in the Clinic: Neurological Implications of Long-haul COVID Infection (1:50 PM-2:00 PM)

Poster/Presentation
Number 001

Objective

To determine the prevalence of neurological and neuropsychiatric symptoms reported 12 weeks (3 months) or more after acute COVID-19 onset in adults.

Background

Neurological and neuropsychiatric symptoms that persist or develop three months after the onset of COVID-19 pose a significant threat to the global healthcare system. These symptoms are yet to be synthesized and quantified via meta-analysis.

Design/Methods

A systematic search of PubMed, EMBASE, Web of Science, Google Scholar and Scopus was conducted for studies published between January 1^st, 2020 and August 1^st, 2021. Studies were included if the length of follow-up satisfied the National Institute for Healthcare Excellence definition of post-COVID-19 syndrome. Additional criteria included reporting of neurological or neuropsychiatric symptoms in individuals with COVID-19. The primary outcome was the prevalence of neurological and neuropsychiatric symptoms reported ≥3 months post onset of COVID-19.

Results Of 1,458 articles, 19 studies, encompassing a total of 11,324 patients, were analysed. Overall prevalence for neurological post-COVID-19 symptoms were: fatigue (37%, 95% CI: 24%-50%), brain fog (32%, 9%-55%), memory issues (27%, 18%-36%), attention disorder (22%, 10%-34%), myalgia (18%, 4%-32%), anosmia (12%, 7%-17%), dysgeusia (11%, 4%-17%) and headache (10%, 1%-21%). Neuropsychiatric conditions included sleep disturbances (31%, 18%-43%), anxiety (23%, 13%-33%) and depression (12%, 7%-21%). Neuropsychiatric symptoms substantially increased in prevalence between mid- and long-term follow-up. Compared to non-hospitalised patients, patients hospitalised for acute COVID-19 had reduced risk of anosmia, anxiety, depression, dysgeusia, fatigue, headache, myalgia, and sleep disturbance at three (or more) months post-infection. Conversely, hospital admission was associated with higher frequency of memory issues (OR: 1.9, 95% CI: 1.4-2.3).

Conclusions

Fatigue, brain fog and sleep disturbances appear to be key features of post-COVID-19 syndrome. Psychiatric manifestations (sleep disturbances, anxiety, and depression) increase significantly in prevalence over time. Randomised controlled trials are necessary to develop intervention strategy to reduce disease burden

Authors/Disclosures
Lavienraj Premraj PRESENTER	Mr. Premraj has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jonathon Fanning, MBBS, PhD (Queensland Health)	Dr. Fanning has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Sung-Min Cho	No disclosure on file

��ɫ��

��ɫ��